Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

NCT03203642 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Autosomal Dominant Polycystic Kidney
ADPKD

Interventions

DRUG: Tesevatinib
DRUG: Placebo

Sponsor

Kadmon, a Sanofi Company